Pacira BioSciences (PCRX) Total Debt (2010 - 2026)

Pacira BioSciences' Total Debt history runs 15 years deep, the most recent figure standing at $367.7 million for Q1 2026.

• In Q1 2026, Total Debt rose 21.11% year-over-year to $367.7 million; the TTM figure through Mar 2026 stood at $367.7 million (up 21.11% YoY), while the FY2025 annual figure was $372.2 million, down 36.41% from the prior year.
• Total Debt was $367.7 million for Q1 2026 at Pacira BioSciences, down from $372.2 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $585.3 million in Q4 2024 to a low of $109.8 million in Q2 2024.
• Historically, Total Debt has averaged $275.8 million across 5 years, with a median of $303.6 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Total Debt sank 65.68% in 2023, then surged 372.63% in 2024.
• A 5-year view of Total Debt shows it stood at $284.7 million in 2022, then sank by 56.5% to $123.8 million in 2023, then jumped by 372.63% to $585.3 million in 2024, then sank by 36.41% to $372.2 million in 2025, then declined by 1.22% to $367.7 million in 2026.
• The last three Total Debt figures came in at $367.7 million (Q1 2026), $372.2 million (Q4 2025), and $376.7 million (Q3 2025), per Business Quant data.